Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.
PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline ...
Pfizer (NYSE:PFE) released detailed Phase 2b results for berobenatide, its investigational monthly GLP-1 receptor agonist for ...
Pfizer and major pharma names draw fresh attention as healthcare rotation, pipeline strength, and patent risks shape the ...
Pfizer (PFE) stock drops 3% as CFO Dave Denton reveals August exit. Cecile Guegan appointed interim CFO while company ...
Zacks Investment Research on MSN
Investors heavily search Pfizer Inc. (PFE): Here is what you need to know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...
Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and entertainment news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results